Adaptimmune Therapeutics PLC (ADAP)

[Watts Watt]

In the last trading session, 1.8 million Adaptimmune Therapeutics plc (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.17. With the company’s per share price at $3.86 changed hands at -$0.04 or -1.03% during last session, the market valuation stood at $635.09M. ADAP’s last price was a discount, traded about -183.16% off its 52-week high of $10.93. The share price had its 52-week low at $3.79, which suggests the last value was 1.81% up since then. When we look at Adaptimmune Therapeutics plc’s average trading volume, we note the 10-day average is 1.52 million shares, with the 3-month average coming to 932.00K.

Analysts gave the Adaptimmune Therapeutics plc (ADAP) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 2.60. If we narrow down to specifics, the data shows that 1 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 4 recommended ADAP as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Adaptimmune Therapeutics plc’s EPS for the current quarter is expected to be -$0.24.

Instantly ADAP was in red as seen at the end of in last trading. With action -6.76%, the performance over the past five days has been red. The drop to weekly highs of 4.22 on Tuesday, 06/22/21 subtracted -1.03% to the stock’s daily price. The company’s shares are showing year-to-date downside of -28.39%, with the 5-day performance at -6.76% in the red. However, in the 30-day time frame, Adaptimmune Therapeutics plc (NASDAQ:ADAP) is -24.17% down. Looking at the short shares, we see there were 3.84 million shares sold at short interest cover period of 5.03 days.

The consensus price target for the stock as assigned by Wall Street analysts is $10.29, meaning bulls need an upside of 62.49% from its current market value. According to analyst projections, ADAP’s forecast low is $4.00 with $17.00 as the target high. To hit the forecast high, the stock’s price needs a -340.41% plunge from its current level, while the stock would need to soar -3.63% for it to hit the projected low.

Adaptimmune Therapeutics plc (ADAP) estimates and forecasts
Data shows that the Adaptimmune Therapeutics plc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -21.38% over the past 6 months, a -11.11% in annual growth rate that is considerably lower than the industry average of 9.00%. Year-over-year growth is forecast to reach -32.30% down from the last financial year.

Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of $1.36 million. 7 analysts are of the opinion that Adaptimmune Therapeutics plc’s revenue for the quarter ending Sep 2021 will be $460k. The company’s revenue for the corresponding quarters a year ago was $930k and $1.19 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 46.20%. The estimates for the next quarter sales put growth at -61.40%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -24.90%. The 2021 estimates are for Adaptimmune Therapeutics plc earnings to increase by 30.10%, but the outlook for the next 5-year period is at 1.00% per year.

SOURCE: https://marketingsentinel.com/2021/06/23/adaptimmune-therapeutics-plc-nasdaq-adap-the-most-interesting-shares-today/